Selected article for: "acute kidney injury and lung strategy"

Author: Liu, Yulan; Xie, Wenjie; Meng, Yang; Sun, Lifang; Yan, Juanjuan; Dong, Weiguo; Zhou, Chenliang; Yu, Zhui
Title: The clinical course of critically ill COVID-19 patients receiving invasive mechanical ventilation with subsequent terminal weaning: Primary data from 11 cases
  • Cord-id: q0lxg6i4
  • Document date: 2021_4_23
  • ID: q0lxg6i4
    Snippet: The coronavirus disease (COVID-19) outbreak was first reported in December 2019 in Wuhan, China. Specific information about critically ill COVID-19 patients receiving invasive mechanical ventilation (IMV) is rare. To describe the clinical course and complications of critically ill patients with COVID-19 who received IMV and were successfully weaned from it. This retrospective study included patients admitted to 3 intensive care units (ICUs) and 1 sub-ICU of Renmin Hospital of Wuhan University an
    Document: The coronavirus disease (COVID-19) outbreak was first reported in December 2019 in Wuhan, China. Specific information about critically ill COVID-19 patients receiving invasive mechanical ventilation (IMV) is rare. To describe the clinical course and complications of critically ill patients with COVID-19 who received IMV and were successfully weaned from it. This retrospective study included patients admitted to 3 intensive care units (ICUs) and 1 sub-ICU of Renmin Hospital of Wuhan University and Wuhan Jin Yin-tan Hospital between December 24, 2019, and March 12, 2020. Eleven patients who had been diagnosed with critically ill COVID-19 according to the World Health Organization interim guidance, received invasive ventilation, and were finally successfully weaned from it, were enrolled in our study. Their presenting symptoms, comorbidity conditions, laboratory values, ICU course, ventilator parameters, treatments, and relative complications were recorded. Of 108 critically ill COVID-19 patients who received invasive ventilation, 11 patients who underwent tracheal extubation or terminal weaning were included. The mean age of the 11 patients was 52.8 years (range, 38–70 years), 8 (72.7%) were male, and 2 were health care workers. The median time from onset of symptoms to dyspnea was 6.6 days (range, 3–13 days), and the median duration of IMV was 15.7 days (range, 6–29 days). All 11 patients presented with acute severe hypoxemic respiratory failure and received IMV, and 1 patient switched to extracorporeal membrane oxygenation assistance. A lung-protective strategy with lower tidal volume ventilation and proper driving pressure is the main strategy of IMV. All patients had extrapulmonary manifestations, including acute kidney injury, hepatic dysfunction, myocardial damage, and/or lymphopenia. Hospital-acquired infections occurred in 7 (63.6%) patients. Critical COVID-19 illness is characterized by acute hypoxemic respiratory failure and subsequent dysfunction of other organs with a high mortality rate. Correct ventilation strategies and other clinical strategies to improve oxygenation based on the skilled trained group and the availability of equipment are the key methods to rescue lives.

    Search related documents:
    Co phrase search for related documents
    • acid base electrolyte and acute ards respiratory distress syndrome: 1
    • acinetobacter baumannii and acute aki kidney injury: 1
    • acinetobacter baumannii and acute ards respiratory distress syndrome: 1, 2, 3, 4
    • acinetobacter baumannii and liver support: 1
    • acinetobacter baumannii and long term hospitalization: 1
    • acinetobacter baumannii and lung injury: 1, 2, 3
    • acute aki kidney injury and liver support: 1, 2, 3
    • acute aki kidney injury and long term hospitalization: 1
    • acute aki kidney injury and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute aki kidney injury and lung protective: 1, 2
    • acute ards respiratory distress syndrome and liver support: 1, 2, 3
    • acute ards respiratory distress syndrome and long duration: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung protective: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung protective strategy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute ards respiratory distress syndrome consistent and lung protective: 1
    • acute severe hypoxemic respiratory failure and lung injury: 1, 2, 3
    • liver support and lung injury: 1
    • long duration and lung injury: 1